Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Director departure
Inv. presentation
Quarterly results
Appointed director

ARGOS THERAPEUTICS INC (ARGS) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/03/2019 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
Docs: "Letter from PricewaterhouseCoopers LLP to the SEC, regarding the statements made in this Current Report on Form 8-K"
02/14/2019 SC 13D/A ForArgos B.V. reports a 2.9% stake in ARGOS THERAPEUTICS INC.
12/03/2018 8-K Resignation/termination of a director
11/19/2018 10-Q Quarterly Report for the period ended September 30, 2018
11/14/2018 NT 10-Q Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:
08/20/2018 10-Q Quarterly Report for the period ended June 30, 2018
08/15/2018 NT 10-Q Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB:
07/20/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/19/2018 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
05/15/2018 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/15/2018 10-Q Quarterly Report for the period ended March 31, 2018
05/09/2018 CT ORDER Form CT ORDER - Confidential treatment order:
04/27/2018 GN Factors of Influence in 2018, Key Indicators and Opportunity within Bottomline Technologies, SkyWest, Pacific Biosciences of California, Argos Therapeutics, Luminex, and Fiserv — New Research Emphasizes Economic Growth
04/25/2018 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/25/2018 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/25/2018 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/25/2018 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/24/2018 8-K Quarterly results
04/19/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Argos Therapeutics Reports Results of Interim Analysis of the ADAPT Trial and Announces Review of Strategic Alternatives - Company to terminate the ADAPT study – - Company has retained Stifel to provide advice on possible strategic alternatives – - Trading in the common stock to be transferred from Nasdaq to the OTCQB Venture Market - DURHAM, N.C., April 19, 2018 -- Argos Therapeutics, Inc. , an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today reported interim results from its randomized, active controlled, open-label, multi-center Phase 3 ADAPT trial of Rocapuldencel-T in combination with sunitinib/standard-of-care for the treatment of newly diagnosed metastat..."
04/02/2018 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
04/02/2018 10-K Annual Report for the period ended December 31, 2017
04/02/2018 4 Katz Richard D (Vice President and CFO) has filed a Form 4 on ARGOS THERAPEUTICS INC
Txns: Granted 22,629 shares @ $0
04/02/2018 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Argos Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights DURHAM, NC, April 02, 2018 -- Argos Therapeutics, Inc. , an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis precision immunotherapy technology platform, today reported financial results and operational highlights for the fourth quarter and full year 2017. Jeff Abbey, CEO of Argos Therapeutics, stated, "Although we faced a very challenging 2017, we have been able to continue the Phase 3 ADAPT clinical trial of Rocapuldencel-T for the treatment of metastatic renal cell carcinoma, and look forward to the next interim data analysis, which we expect to occur during the second quarter of 2018. In addition to cont..."
04/02/2018 GN Argos Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights
03/30/2018 4 Harrelson Lori R. (Vice President of Finance) has filed a Form 4 on ARGOS THERAPEUTICS INC
Txns: Granted 22,629 shares @ $0
03/30/2018 4 Nicolette Charles A. (CSO and Vice President of R&D) has filed a Form 4 on ARGOS THERAPEUTICS INC
Txns: Granted 27,150 shares @ $0
03/30/2018 4 Abbey Jeffrey D (CEO) has filed a Form 4 on ARGOS THERAPEUTICS INC
Txns: Granted 67,887 shares @ $0
03/28/2018 GN Argos Therapeutics to Report Fourth Quarter and Year-End 2017 Financial Results and Operational Highlights on Monday, April 2, 2018
03/07/2018 8-K Other Events
03/01/2018 GN Detailed Research: Economic Perspectives on Navigant Consulting, CalAmp, Sonoco Products, Argos Therapeutics, K2M Group, and Altra Industrial Motion — What Drives Growth in Today's Competitive Landscape
02/16/2018 8-K Quarterly results
02/15/2018 GN Argos Announces Issuance of Patent Covering the Foundation for Manufacturing its HIV Immunotherapy
02/14/2018 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
02/05/2018 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "Amended and Restated Sales Agreement, by and between the Company and Cowen and Company, LLC",
"Opinion of Wilmer Cutler Pickering Hale and Dorr LLP",
"Argos Obtains Option to License PD1 Checkpoint Inhibitors - Data showing synergy between PD1 checkpoint inhibition and analogue of Rocapuldencel-T in a preclinical model of renal carcinoma presented at ASCO-SITC - - Company to host a conference call on Tuesday, February 6, 2018 at 8:30 a.m. ET - DURHAM, N.C., Feb. 05, 2018 -- Argos Therapeutics Inc. , an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today announced that it has entered into an option agreement with Pharmstandard International, S.A. and Actigen Limited under which the Company has an option to license a group of fully human anti-PD1 monoclonal antibodies and related technology. Results of a preclinic..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy